EDGAR LOUIS MILFORD
Pilots at Ctr St, Dover, MA
License number
Massachusetts C1058147
Category
Airmen
Address
Address
76 Centre St, Dover, MA 02030
Professional information
Novel T-Cell Membrane Protein (Tirc7), Peptides And Antibodies Derived Therefrom And Uses Thereof
US Patent:
2003012, Jul 3, 2003
Filed:
May 13, 2002
Appl. No.:
10/145012
Inventors:
Nalan Utku - Berlin, DE
Steven Gullans - Natick MA, US
Edgar Milford - Dover MA, US
Steven Gullans - Natick MA, US
Edgar Milford - Dover MA, US
Assignee:
Brighams and Womens Hospital Inc.
International Classification:
G01N033/53
US Classification:
435/007100
Abstract:
Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies being capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Furthermore, vectors comprising the aforementioned polynucleotides and host cells transformed therewith as well as their use in the production of the above-defined proteins, peptides or polypeptides are described. Additionally, pharmaceutical and diagnostic compositions are provided comprising any one of the afore described polynucleotide, vector, protein, peptide, polypeptide, or antibody. Furthermore, methods and uses for modulating immune responses through the novel TIRC7 membrane protein as well as pharmaceutical compositions comprising agents which act on the TIRC7 membrane protein or its ligand are described. Also, the use of said polynucleotide, vector, protein, peptide, polypeptide, or antibody for the preparation of pharmaceutical compositions for use in organ transplantation, for the treatment of autoimmune, allergic or infectious diseases, or for treatment of tumors is provided. Furthermore, methods for modulating (antigen-specific) T cell unresponsiveness inducing maintaining or reversing T cell unresponsiveness by inhibiting or stimulating an (unresponsive) T cell through the novel TIRC7 membrane protein are encompassed herein.
T-Cell Membrane Protein (Tirc7), Peptides And Antibodies Derived Therefrom And Uses Thereof
US Patent:
7931901, Apr 26, 2011
Filed:
Aug 25, 2006
Appl. No.:
11/510868
Inventors:
Nalan Utku - Berlin, DE
Steven R. Gullans - Natick MA, US
Edgar L. Milford - Dover MA, US
Steven R. Gullans - Natick MA, US
Edgar L. Milford - Dover MA, US
Assignee:
The Brigham and Women's Hospital, Inc. - Boston MA
International Classification:
A61K 39/395
US Classification:
4241441, 514825, 4241541
Abstract:
Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies being capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Furthermore, vectors comprising the aforementioned polynucleotides and host cells transformed therewith as well as their use in the production of the above-defined proteins, peptides or polypeptides are described. Additionally, pharmaceutical and diagnostic compositions are provided comprising any one of the afore described polynucleotide, vector, protein, peptide, polypeptide, or antibody. Furthermore, methods and uses for modulating immune responses through the novel TIRC7 membrane protein as well as pharmaceutical compositions comprising agents which act on the TIRC7 membrane protein or its ligand are described. Also, the use of said polynucleotide, vector, protein, peptide, polypeptide, or antibody for the preparation of pharmaceutical compositions for use in organ transplantation, for the treatment of autoimmune, allergic or infectious diseases, or for treatment of tumors is provided.
Novel Genes Tzap7/A, Tzap7/B And Tzap7 Involved In T Cell Activation And Uses Thereof
US Patent:
2007021, Sep 13, 2007
Filed:
Jan 16, 2007
Appl. No.:
11/654267
Inventors:
Nalan Utku - Berlin, DE
Edgar Milford - Dover MA, US
Edgar Milford - Dover MA, US
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
Described are generally immune response cDNA TZap7/A, TZap7/B and TZap7 polynucleotides encoding novel proteins involved in modulation of immune responses and antibodies recognizing said proteins. Furthermore, vectors comprising the aforementioned polynucleotides and host cells transformed therewith as well as their use in the production of the above-defined proteins are described. Additionally, pharmaceutical and diagnostic compositions are provided comprising any one of the afore-described polynucleotides, vectors, proteins, or antibodies. Furthermore, methods and uses for modulating immune responses through the novel TZap protein as well as pharmaceutical compositions comprising agents which act on the TZap protein or its ligand are described. Also, the use of said polynucleotides, vectors, proteins or antibodies for the preparation of diagnostic and pharmaceutical compositions for use in organ transplantation, for the treatment of autoimmune, allergic or infectious diseases, or for treatment of tumors is provided.
Novel T-Cell Membrane Protein (Tirc7), Peptides And Antibodies Derived Therefrom And Uses Thereof
US Patent:
2005027, Dec 8, 2005
Filed:
May 10, 2005
Appl. No.:
11/126841
Inventors:
Nalan Utku - Berlin, DE
Steven Gullans - Natick MA, US
Edgar Milford - Dover MA, US
Steven Gullans - Natick MA, US
Edgar Milford - Dover MA, US
International Classification:
A61K039/395, A61K038/17, C07K014/74, C07K016/28
US Classification:
424144100, 536023500, 530350000, 435069100, 435320100, 435325000, 530388220, 514012000
Abstract:
Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies being capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Furthermore, vectors comprising the aforementioned polynucleotides and host cells transformed therewith as well as their use in the production of the above-defined proteins, peptides or polypeptides are described. Additionally, pharmaceutical and diagnostic compositions are provided comprising any one of the afore described polynucleotide, vector, protein, peptide, polypeptide, or antibody. Furthermore, methods and uses for modulating immune responses through the novel TIRC7 membrane protein as well as pharmaceutical compositions comprising agents which act on the TIRC7 membrane protein or its ligand are described. Also, the use of said polynucleotide, vector, protein, peptide, polypeptide, or antibody for the preparation of pharmaceutical compositions for use in organ transplantation, for the treatment of autoimmune, allergic or infectious diseases, or for treatment of tumors is provided. Furthermore, methods for modulating (antigen-specific) T cell unresponsiveness inducing maintaining or reversing T cell unresponsiveness by inhibiting or stimulating an (unresponsive) T cell through the novel TIRC7 membrane protein are encompassed herein.
T-Cell Membrane Protein (Tirc7) And Peptides Derived Therefrom
US Patent:
7863418, Jan 4, 2011
Filed:
May 10, 2005
Appl. No.:
11/126866
Inventors:
Nalan Utku - Berlin, DE
Steven R. Gullans - Natick MA, US
Edgar L. Milford - Dover MA, US
Steven R. Gullans - Natick MA, US
Edgar L. Milford - Dover MA, US
Assignee:
The Brigham and Women's Hospital, Inc. - Boston MA
International Classification:
C07K 14/705, A61K 38/17
US Classification:
530350, 514 12
Abstract:
Described are a T cell immune response cDNA 7 (TIRC7) encoding a T-cell transmembrane protein, peptides and polypeptides derived therefrom and antibodies recognizing such (poly)peptides. Peptides, polypeptides and antibodies capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Vectors comprising polynucelotides encoding such polypeptides and peptides, host cells transformed therewith, and their use in the production of such, peptides or polypeptides are also described.
Monoclonal Antibodies For Human Tissue Cross-Matching
US Patent:
4517289, May 14, 1985
Filed:
Aug 18, 1982
Appl. No.:
6/409183
Inventors:
Edgar L. Milford - Dover MA
Charles B. Carpenter - Weston MA
Jean M. Paradysz - Brighton MA
Charles B. Carpenter - Weston MA
Jean M. Paradysz - Brighton MA
Assignee:
Brigham and Women's Hospital - Boston MA
International Classification:
G01N 3354, C12N 500, C12N 1500, C12R 191, A61K 39395
US Classification:
435 7
Abstract:
Immortal, antibody-producing, hybridomally-produced clones which produce antibodies that react specifically with human HLA antigens and which are produced from rat lymphocyte cells sensitized against cells from a rat strain having different histocompatibility antigens are disclosed along with methods of producing the clones and antibodies and methods of using the antibodies in tissue crossing tests.